Encompass Health Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Encompass Health Corporation on December 1, 2025. The filing serves as a Regulation FD disclosure to inform investors and analysts of upcoming meetings scheduled for December 2 and December 3, 2025. The report primarily reiterates the company's full-year 2025 financial guidance previously issued in late October 2025.
Key Financial Metrics and Guidance
The filing provides updated full-year 2025 guidance ranges for non-GAAP measures. The company does not provide GAAP guidance due to the unpredictability of certain items outside its control.
- Net Operating Revenue: $5,905 million to $5,955 million
- Adjusted EBITDA: $1,235 million to $1,255 million
- Adjusted EPS (Continuing Operations): $5.22 to $5.37
The filing notes reasonably estimable GAAP measures for 2025 that would be included in an Adjusted EBITDA reconciliation if other items were predictable:
- Interest Expense and Amortization of Debt Discounts/Fees: Approximately $125 million
- Amortization of Debt-Related Items: Approximately $10 million
The filing text does not provide specific values for current period revenue, profit, cash flow, margins, debt, or liquidity, as this is a guidance reaffirmation rather than a quarterly earnings report.
Material Changes
There are no material changes to the financial guidance reported in this filing. The company explicitly states it is reiterating the guidance previously reported in the Form 8-K dated October 29, 2025, and the earnings conference call held on October 30, 2025.
Outlook, Risks, and Contingencies
Management's outlook remains consistent with prior communications. The filing includes extensive forward-looking statements and identifies numerous risks that could cause actual results to differ materially from estimates:
- Operational Risks: Infectious disease outbreaks affecting patient volumes and staffing; cybersecurity breaches; and challenges in attracting and retaining healthcare professionals.
- Regulatory and Reimbursement Risks: Changes in federal and state healthcare regulations; increased Medicare audit activity; delays or suspensions in reimbursement from governmental or private payors; and coverage determinations by Medicare Administrative Contractors.
- Financial and Legal Risks: Adverse outcomes in lawsuits and regulatory proceedings; costs related to professional liability claims; and the impact of stock price on share repurchase programs.
- Economic Risks: General economic downturns, capital market instability, trade wars, and increases in construction material costs due to tariffs.
The company notes that items such as government settlements, legal fees, mark-to-market adjustments, and restructuring costs are excluded from non-GAAP guidance as they are not indicative of ongoing operations.
Investor Verification Checklist
- Verify the company's actual performance against the reiterated full-year 2025 guidance ranges upon the release of the Q4 2025 results.
- Monitor upcoming investor meetings on December 2-3, 2025, for any qualitative updates on operational challenges not captured in the guidance.
- Review the company's Form 10-K (2024) and Form 10-Q (Q3 2025) for historical context on the "reasonably estimable" GAAP measures mentioned (interest expense and debt amortization).
- Track developments in Medicare audit activity and reimbursement appeals, as these are cited as significant risks to revenue recovery.
- Assess the impact of labor market conditions and potential union activity on the company's ability to control labor costs within the guided Adjusted EBITDA range.